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Abstract
Background: Shivering is a frequent complication following surgery and anaesthesia. A large variety of studies
have been reported that nefopam may be efficacious for the prevention and treatment of perioperative shivering.
Regrettably, there is still no conclusion of the efficacy and safety of nefopam for the prevention of perioperative
shivering. The aim of this analysis is to evaluate the efficacy of nefopam for the prevention of perioperative
shivering in patients undergoing different types of anaesthesia compared with placebo group and other active
interventions.
Methods: PubMed, EMBASE, Cochrane Central Register of Control Trials were systematically searched for potentially
relevant trials. Trial quality and extracted data were evaluated by two authors independently. Dichotomous data on
the absence of shivering was extracted and analysed by using relative risk (RR) with 95 % confidence interval (CI).
Continuous outcome was abstracted and analysed by using weighted mean difference (WMD) with 95 %
confidence interval (CI). Outcome data was analysed by using random effect model or fixed effect model in
accordance with heterogeneity.
Results: Compared with placebo, prophylactic administration of nefopam significantly reduced the risk of perioperative
shivering not only in the patients under general anaesthesia but also neuraxial anaesthesia (RR 0.08; 95 % CI 0.05-0.13). As
compared with clonidine, nefopam was more efficacious in the prevention of perioperative shivering (RR 0.34; 95 % CI
0.17-0.70). Nefopam has no influence on the extubation time (WMD 0.92; 95 % CI −0.15-1.99).
Conclusion: Our analysis has demonstrated that nefopam is associated with the decrease of risk of perioperative
shivering following anaesthesia without influencing the extubation time.
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Background
Shivering is a distressing and frequent side effect during
the intra-operative period [1], which might hinder moni-
toring [2]. Shivering never causes direct demise of pa-
tients and it is unlikely to become chronic. However, it
is associated with the increase of oxygen consumption,
which would endanger a patient with compromised car-
diac function. The mechanism of perioperative shivering
is not completely clear. Shivering may act as a response
to hypothermia. Whereas, shivering happens even with
normothermia in the perioperative period, suggesting
that other origins than heat loss and subsequent de-
crease in body temperature may lead to the development
of shivering [3]. Moreover, keeping patients normother-
mia is not always available. Thus, it is essential to pre-
vent shivering by using pharmacologic interventions in a
special case for selected patients.
A large variety of regimens have been demonstrated to
be efficacious in the prevention and treatment of posta-
nesthetic shivering, such as α2-agonist [4, 5], tramadol
[1, 6], meperidine [7, 8], serotonin-3 receptor antagonist
[9]. There is still no “gold standard” intervention for the
prevention of perioperative shivering. To our knowledge,
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nefopam may hold the best promise due to its efficacy
[10–12] without any serious adverse effects [13].
Nefopam, a benzoxazocine substance, is structurally
related to orphenadrine and dyphehydramine [14]. Nefo-
pam is neither a non-steroidal anti-inflammatory drug
nor an opiate [15]. Nefopam is not associated with re-
spiratory inhibition [16]. The mechanisms of nefopam
involved in the anti-shivering and thermoregulatory
action are not completely demonstrated. Nefopam in-
hibits the synaptic reuptake of dopamine, norepineph-
rine, and serotonin in an amphetamine fashion [17].
Nefopam affected thermoregulatory response via α2
adrenoceptors [18].
The aim of this review is to investigate the effective-
ness of nefopam for preventing perioperative shivering
and the influence of nefopam on the extubation time.
The secondary aim of this analysis is to compare the ef-
ficacy of nefopam with the other active interventions for
the prevention of perioperative shivering.
Methods
We systematically screened the Medline (1966 - February
2015), EMBASE (1980 - February 2015), Cochrane
Central Register of Controlled Trials (CENTRAL) (The
Cochrane Library 2015, Issue 2) by using different search
strategies. Potentially relevant randomised controlled trials
(RCT) were searched by using search methods found in
(Appendix 1 MEDLINE silver platter); (Appendix 2
EMBASE silver platter); (Appendix 3 CENTRAL). Grey
literature and Conference proceedings were manually
searched. Relevant investigators were contacted for sup-
plemental data and special question. Additional articles
were identified from reference lists of retrieved articles.
No language restriction was applied in this study. The date
of last search was February 18, 2015.
Randomised controlled trials of prophylactic adminis-
tration of nefopam to prevent perioperative shivering
were included in this analysis. Only standard randomised
controlled trials were taken into account; quasi-
randomized controlled studies, cluster-trials and cross-
over trials were excluded. Active controlled trials without
placebo group or inactive group were excluded. Studies
with limited number of patients were excluded. Data from
retrospective studies, nonsurgical settings studies or ex-
perimental studies in volunteers were not included. We
only considered trials that investigated prophylactic use of
nefopam for preventing perioperative shivering in adults
undergoing surgery. Different doses of nefopam were
tested in the included studies. We excluded the trials that
were related to the treatment of shivering.
Each title and abstract of references was screened by
two authors to exclude obvious irrelevant articles with
disagreement resolved by consensus. If potentially rele-
vant, the complete articles were retrieved. Two reviewers
independently read the articles in complete form to de-
termine the final inclusion. Consensus of inclusion of
the studies was reached by discussion. Reviewers were
not blinded to trial authors, institutions, journal of pub-
lication, and results of study.
The following inclusion criteria were used for potentially
pertinent studies: random allocation, comparison of nefo-
pam versus placebo, performed on surgical patients with
no restraints on dose and timing of administration. The
exclusion criteria were duplicate publications, nonhuman
trials, without main outcome, studies in healthy volunteers
and data from abstracts or letters.
Data were collected by two investigators from the se-
lected studies, with disagreement resolved by consensus.
We obtained the information on patients, anesthetic
methods, interventions, outcomes, body temperature,
different doses of nefopam and adverse effects.
For dichotomous outcome, data was extracted as the
number of patients with outcome event and the number
of patients in the treatment group and placebo group. A
large variety of efficacy endpoints of shivering were re-
ported in these studies. In order to reduce the interpret-
ational bias, we only extracted efficacy data on complete
absence of shivering. For continuous outcome, data was
expressed as mean value and standard deviation (SD).
Some of the included trials were multiple-arm studies.
When we extracted the continuous data from these tri-
als, it was necessary to combine multiple groups into a
single one. The SD and mean values of the combined
group were calculated according to the method of the
Cochrane Handbook of Systematic Review of interven-
tions [19] (Table 1).
The risk of bias of the included studies was assessed
by using the Cochrane Collaboration’s protocol [20].
The articles were reviewed to arrive a final score if there
was a discrepancy.
Relative risk (RR) with pertinent 95 % confidence in-
tervals (CI) were calculated for binary outcomes. A stat-
istical significance between nefopam group and control
group was assumed if the 95 % CI of the RR excluded 1.
In the presence of significant heterogeneity, we intended
to use random-effect method. If there was not statisti-
cally significant heterogeneity, the fixed effect method
was used. As an estimate of statistically significant differ-
ence between nefopam and untreated control group for
continuous variable, we calculated weighted mean differ-
ence (WMD) with 95 % CI. If the 95 % CI of WMD did
not include 0, we considered that the difference between
nefopam and control was significant. Heterogeneity and
inconsistency were evaluated by Q and I2 test respect-
ively. When the P value of Q test was greater than 0.10
and I2 was less than 50 %, we regarded it as homogen-
eity. The subgroup analysis was based on different
anesthetic methods, general anaesthesia and neuraxial
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anaesthesia. Two sensitivity analyses were planned a
prior to explore the heterogeneity. First, calculation that
used the fixed effects model was repeated by using the
random effect model. Second, some trials were retracted
from the journal due to ethical reasons. Therefore,
analysis was performed with or without these retracted
articles. The reporting bias was assessed by visual in-
spection into funnel plots [21]. Meta-analysis was con-
ducted by using Review Manager 5.1.
Results
Included studies
Through electronic searches, snowballing, manual search,
contact with the authors, 133 potentially eligible articles
were obtained. The detail of flowchart of the studies in-
cluded in this study was shown in Fig. 1.
A total of 124 studies were subsequently excluded. 65
reports were duplicated from different databases. 53
studies were obviously irrelevant trials of this analysis
according to the titles and abstracts. One trial was not
randomised controlled trials [22]. One trial lacked
non-controlled trial or placebo group [7]. One trial
was for the prevention of amphotericin-B induced
shivering [23]. We excluded two studies of nefopam
for the treatment of intra-operative shivering [24, 25].
Finally, in one trial sample size in each group less than
10 was excluded [26].
Nine eligible randomized clinical trials were eventually
included in this analysis, which were published between
1992 and 2013 [13, 27–34] (Table 2). 925 participants
from 9 studies were analysed in this study with 474 pa-
tients assigned to nefopam group, 131 patients allocated
to clonidine group and 320 participants to placebo
group. The sample size of enrolled studies ranged from
30 to 371. Six randomised clinical trials included in this
analysis were undergoing general anaesthesia. The pa-
tients in two studies were undergoing neuraxial anaes-
thesia. In only one study, subjects were under conscious
sedation. Six trials involved more than one active inter-
vention or studied multiple experimental interventions.
Of all trials nefopam was given intravenously. Nefopam
was administered at different time points. In three stud-
ies nefopam was given before surgery. In 6 trials nefo-
pam was administered at the end of surgery. Among all
the enrolled studies, the participants in only one trial
underwent active cooling. Three articles were retracted
from the published journals due to ethical reason [29,
30, 35]. In five studies, sample size calculation was car-
ried out to control, type one and type two errors.
Risk of bias in included studies
The quality assessment of the included studies was
based on: method of randomization, concealment of
allocation, use of blinding, and completeness of data.
The detail of the risk of bias was presented in Fig. 2.
The funnel plot was presented in Fig. 4 and there was
not evident publication bias.
Effects of intervention
Risk of perioperative shivering
9 studies reporting on the episodes of shivering finally
entered into the analysis, with 474 patients allocated to
nefopam group and 320 patients to placebo group. The
control group event rate ranged from 16.7 % to 100 %.
Overall analysis demonstrated that nefopam was associ-
ated with significant reduction in the incidence of shiver-
ing (RR,0.08, 95 % CI 0.05-0.13)as shown in Fig. 3.
Statistical tests indicated that there was no substantial het-
erogeneity across the studies (Chi2 = 3.71, P = 0.88, I2 =
0 %), therefore data on the incidence of shivering was
combined by using the fixed effect model.
Sensitivity analysis
1 We applied two sensitivity analyses to the incidence
of shivering compared nefopam with placebo.
The fixed effect model favoured prophylactic use of
nefopam (RR 0.08, 95 % CI 0.05- 0.13).
The random effect model also favoured the
administration of nefopam (RR 0.10, 95 % CI 0.06-0.15).
2 There were three articles retracted from published
journals due to ethnic reasons. This sensitivity
analysis considered the retracted studies.
The incidence of shivering was significantly lower in
the nefopam group than the placebo group without
the retracted articles (RR 0.09, 95 % CI 0.05- 0.17).
Subgroup analysis
Subgroup analysis focused on the different methods
of anaesthesia, general anaesthesia and neuraxial an-
aesthesia, as shown in Fig. 5.
Table 1 Formula for combining groups of continuous data
Group 1 Group 2 Combined group
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General anaesthesia: the RR favoured administration
of nefopam (RR 0.10, 95 % CI 0.06, 0.16).
Neuraxial anaesthesia: the RR favoured prophylactic
administration of nefopam (RR 0.05, 95 % CI 0.01, 0.18).
The effect of nefopam on extubation time
Four studies tested on the effect of nefopam on extubation
time compared to the control group. When the data was
combined, the extubation time in placebo group was earlier
than nefopam group. However, the difference between the
two groups did not reach statistical significance (WMD0.92;
95 % CI −0.15, 1.99), the data was presented in Fig. 6.
Comparison of nefopam with clonidine
Clonidine was the most frequently tested substance.
Three studies reported on the risk of shivering compar-
ing nefopam with clonidine in total of 407 patients, with
276 allocated to nefopam group and 131 to clonidine
group. When the data was combined, the risk of
perioperative shivering was significantly lowered in pa-
tients received nefopam in comparison with clonidine
(RR, 0.34, 95 % C I0.17-0.70). There was no statistical
heterogeneity between nefopam group and clonidine
group (Chi2 = 0.57, P = 0.75, I2 = 0 %), as shown in Fig. 7.
Discussion
We performed a meta-analysis following the guideline of
methodology of the Cochrane Handbook for systemic
review of interventions. There are two main results in
this research. First, this analysis revealed that nefopam
was associated with the reduction of rate of shivering
not only under general anaesthesia but also neuraxial
anaesthesia. As compared with clonidine, nefopam was
more efficacious for the prevention of postanaesthetic
shivering during the perioperative period. Second, as
compared with placebo group, the extubation time in
nefopam group did not show statistically significant dif-
ference. Besides, none of the enrolled studies reported
68 potentially trials were 
screened 
53 articles excluded by 
scteening the titles and 
abstracts
65 trials were 
subsequently excluded 
due to duplicated from 
different databases
1 were not RCT
1 lack control group
1 trial was not in surgical 
setting
1 limited sample size
2 were nefopam for 
treatment of shivering 
9 studies were finally included in 
this analysis
15 articles were retrieved in 






Fig. 1 Flow chart of analyzed studies
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Table 2 Demographic data of included studies
Study Surgical setting Type of anesthesia Comparisons (No. of patients) Time of administration Temperature
Piper 2004 [29] Orthopedic or abdominal General anesthesia Nefopam0.2 mg/kg (73); Nefopam0.1 mg/kg (75);
Nefopam0.05 mg/kg (76); Clonidine1.5 μg/kg (73);
Placebo (74)
At the end of surgery Rectal temperature
Bilotta 2001 [33] Craniotomy General anesthesia Nefopam0.12 mg/kg (20); Placebo (20) At the end of surgery Bladder temperature
Piper 1999 [30] Abdominal or orthopedic General anesthesia Nefopam0.15 mg/kg (20); Clonidine3μg/kg (20);
placebo (20)
At the end of surgery Rectal temperature
Bilotta 2002 [13] Lower limb orthopedic Neuraxial anesthesia Nefopam0.15 mg/kg (30); Tramadol0.5 mg/kg (30);
Placebo (30)
Before anesthesia Urinary-bladder temperature
Bilotta 2005 [28] Interventional neuroradiology Conscious sedation Nefopam0.15 mg/kg (32); Clonidine3μg/kg (38);
Placebo (31)
Before anesthesia Bladder temperature
Rohm 2005 [27] Abdominal or urological General anesthesia Physostigmine2mg (31); Nefopam10mg (30);
Placebo (28)
At the end of surgery Tympanic temperature
Kamal 2011 [34] Orthopedic Neuraxial anesthesia Nefopam0.2 mg/kg (76); Ketamine +midazolam (75);
placebo (75)
Before anesthesia Tympanic temperature
Piper 1998 [31] Orthopedic or abdominal General anesthesia Nefopam0.15 mg/kg (15); Placebo (15) At the end of surgery Rectal temperature












on any serious side effect of nefopam, such as respira-
tory depression or cardiovascular effects.
To our knowledge, this is the first meta-analysis of
nefopam for preventing perioperative shivering. The
methodological quality of most of the included studies
was of high quality. There was a large sample size in this
analysis, so it was possible to determine the significant
difference between the nefopam group and control
group. As a comprehensive search has been done by our
research group, it is nearly impossible that any import-
ant evidence has been ignored.
The aetiology of perioperative shivering is related to
hypothermia, decreased sympathetic activity, pyrogen
release, postoperative pain, adrenal suppression, depres-
sion of vasoconstriction following anaesthesia, blood
loss, duration of surgery et al., [36] it has to be kept in
mind that maintaining body core temperature have a
major effect on the risk of perioperative shivering. Never-
theless, we intentionally kept the patients hypothermic
[37] sometimes and it is impossible to keep the body core
temperature within normal range all the time. Moreover,
shivering occurred even in normothermic patients [38].
Therefore, simple and inexpensive pharmacological strat-
egy is encouraged by anesthesiologists.
A large variety of pharmacological regimens were pro-
posed for the treatment or prevention of shivering. Most
of these interventions are efficacious for perioperitive
shivering. From the indirect comparison of previous
Meta-analysis, nefopam was more efficacious than other
interventions [10–12]. This is consistent with our ana-
lysis that nefopam was more efficacious than clonidine
from the direct comparisons of the included trials. Not-
withstanding, there were significantly clinical and statis-
tical heterogeneity among the included studies and
report of direct comparison was sparse.
Among all the pharmacological interventions, cloni-
dine was the most frequently reported drug. According
to the previous randomized controlled trials and meta-
analysis, clonidine was effective in the treatment and pre-
vention of postanesthetic shivering. However, clonidine
Fig. 2 Risk of bias graph
Fig. 3 The effect of nefopam on the perioperative shivering
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Fig. 5 The effect of nefopam on perioperative shivering under different anesthesia
Fig. 4 Funnel plots for the influence of nefopam on the incidence of peri-operative shivering
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was associated with some side effects, for instance, seda-
tive effect, hypotension and bradycardia. Thus, these side
effects limited its use. The opioids, such as tramadol, me-
peridine, alfentanil were also effective in the prevention
and treatment of shivering. Nonetheless, these drugs were
related to the risk of respiratory depression and postoper-
ative nausea and vomiting (PONV). According to all of
the enrolled studies, nefopam was not associated with the
increase of the risk of any serious side effect, which con-
tribute much to its safety. None of the included studies re-
ported on any side effect of nefopam. This is inconsistent
with the previous reports [7, 39, 40]. This is probably be-
cause the subjects of most of the included studies were
under general anaesthesia.
It is encouraging that nefopam may possess a specific
shivering effect. Alfonsi et al. has shown that nefopam
caused a small increase in the core temperature by low-
ering the shivering threshold and without influencing
sweating and vasoconstriction thresholds, therefore min-
imizing heat loss [41]. Whereas, the other antishivering
drugs, such as clonidine [42], meperidine [43], volatiles
reduce both shivering and vascular threshold [44], tama-
dol [45], thus leading to greater heat loss.
There are several limitations in our analysis. Firstly,
the methods of reporting the scores of perioperative
shivering were different between the trials in this ana-
lysis, most of the included studies used Wrench et al.
evaluation [46], meanwhile, some trials used their own
scoring systems. In this analysis, we only abstracted bin-
ary data on absence of shivering to minimise the inter-
pretational risk. Secondly, the sample size of some trials
was limited. Small sample size may overestimate the
efficacy of nefopam in the prevention of shivering com-
pared with large trial. Thirdly, the baseline of control
event rate has a large variability. With extremely fre-
quent control event rate, it may exaggerate the interven-
tion’s performance. The patients whom anesthesiologists
see in daily clinical work do not have such a high fre-
quent incidence of shivering. This phenomenon chal-
lenges the external clinical applicability of this study.
Fourthly, reports of the adverse effects were sparse.
However, lack of reports does not represent that none
occurred. None of the included studies reported on the
injection pain, probably because most of the included
studies were under general anaesthesia. This was not in
agreement with previous study reporting high incidence
of injection pain. Finally, in this meta-analysis, reviewers
were not blinded to study authors, which might increase
the risk of bias. In the future study, investigators should
be blinded to study authors, institutions, journal of pub-
lication, and results of study.
Conclusions
In conclusion, we have demonstrated that nefopam in-
hibit perioperative shivering without producing
hypotension and sedative of α-2 agonist and respiratory
influence of opiates. The better prophylactic antishiver-
ing efficacy of nefopam and the side effects of other in-
terventions suggest that among all the interventions,
nefopam may hold the best promise. However, side ef-
fects of nefopam need to be investigated. Besides, direct
comparison of nefopam with other drugs, such as trama-
dol, meperidine is stillke needed to confirm the relative
efficacy.
Fig. 7 The influence of nefopam on the peri-operative shivering in comparison with clonidine
Fig. 6 The infuence of nefopam on the extubation time
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Appendix
Appendix 1 MEDLINE search strategy
#1 nefopam
#2 “nefopam” [Mesh]
#3 #1 OR #2
#4 shivering
#5”shivering” [Mesh]
#6 #4 OR #5
#7 #3 AND #6
#8 #7 Filters Randomized controlled trial
Appendix 2 EMBASE search strategy
#1 nefopam
#2 “nefopam” [EMTREE]
#3 #1 OR #2
#4 shivering
#5 “shivering” [EMTREE]
#6 #4 OR #5
#7 #3 AND #6
#8 #7 Filters Randomized controlled trial
Appendix 3 Search strategy for CENTRAL, The Cochrane
Library
#1 MeSH descriptor nefopam explode all trees
#2 nefopam
#3 #1 OR #2
#4 MeSH descriptor shivering explode all trees
#5 shivering
#6 #4 OR #5
#7 #3 AND #6
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